Background: HCV was considered a major health problem worldwide before the discovery of direct acting antiviral therapy. Patients with chronic HCV and decompensated cirrhosis are not uncommon and represent the greatest therapeutic challenge.
Introduction
THE discovery of DAAs represented a revolution in the management of chronic HCV infection [1] .
Among patients with chronic hepatitis C, those with decompensated cirrhosis represent the greatest therapeutic challenge [2] . Additionally, HCV G4 patients with decompensated cirrhosis not attracted as much attention in large scale clinical trials as that afforded to other HCV genotypes [3] .
Moreover, the the safety, tolerability and efficacy of DAAs regimens have not been extensively studied in patients with decompensated cirrhosis [4] .
Thus, patients with decompensated disease were largely untreated and the decision to treat them may be difficult. Such patients present a complex clinical issue that dictates that experienced personnel administer therapy if at all possible [5] .
Therefore, this real-world, open label, observational study was conducted to assess the efficacy and safety of DAAs therapy in the treatment of a group of Egyptian patients with chronic hepatitis C genotype 4 and decompensated cirrhosis.
Subjects and Methods
In the period from March 2017 to September 2017, a total of 40 Egyptian patients with chronic HCV genotype 4 infection and decompensated cirrhosis which were the subject of the present study were selected and identified from Tanta Liver Center and outpatient clinic of Internal Medicine Department Tanta University. The ribavirin dose was 1000 or 1200mg in patients <75 or ≥75kg respectively or 600mg for all patients with a hemoglobin level <12gm/dl. The primary end point is Sustained Virologic Response (SVR) at 12 weeks after the end of treatment (SVR 12). 32 patients (80%) were treated with Sofosbuvir (400mg) plus Ledipasvir (90mg) ± Ribavirin and the remaining 8 (20%) patients were treated with Sofosuvir (400mg) plus Daclatasvir (60mg) ± Ribavirin for either 12 or 24w according to ribavirin use. Also, treatment-related adverse events as well as any complications observed during the study were recorded.
Results
• Values are expressed as mean ± SD; n=30.
• The significance of difference was analyzed by one-way ANOVA and Tukey test using computer Graph Pad InStat.
• ANOVA was significant at p<0.05.
• Group having (***) were significant at p<0.001.
• Group having (**) were significant at p<0.01.
• Group having (*) were significant at p<0.05.
• Otherwise insignificants at p>0.05.
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Discussion
Analysis of the demographic data of our study group (Table 1) revealed that the age of our study group ranged from (29-76) years, with a mean age of 57 ± 10.95 and this is compatible with what was reported in 2 other studies (57 ±9 in Deterding et al., [6] and (53-63) years in Charlton et al., [7] ).
In relation to sex, 24 (60%) of our study group were males and the remaining 16 patients (40%) were females, a finding that indicates that HCV infection is common among males in this area of Nile Delta.
Similar results were reported by 2 national [8, 9] and many other international studies [6,7,10,11] who also reported increased incidence of HCV infection among males (77.3%, 77.1%, 67%, 59%, 63% and 73%) respectively. This sex effect cannot be clearly explained, but might be related to their unique life-style subjecting them more to both schistosomal and viral liver disease.
All our patients with chronic HCV and decompensated cirrhosis (100%) are from rural areas. This may be attributed to the increased incidence of schistosomal and viral liver disease in this endemic area across the Nile Delta.
Review of laboratory findings in our study group revealed, significant improvement in the level of serum albumin and transaminases, while a non significant improvement was observed in serum bilirubin 12 weeks after the end of treatment with almost no change in INR. A finding that indicates not only the safety of DAAs therapy regarding liver functions, but also surprisingly rapid improvement of some of liver function parameters (transaminases and serum albumin) towards restoration of normal liver functions in this group of critically ill patients. Moreover, the quick normalization of liver enzymes during and 12w after the end of treatment indicates marked improvement in the necroinflammatory process in the diseased liver.
Review of relevant publications revealed some discrepancies between our results and the other national and international studies. Not surprisingly, the single national study conducted by Salama et al., [12] reported similar results in a group of Egyptian HCV G4 and decompensated cirrhosis. Also, 3 other international studies Meanwhile, there was a non-significant decrease in Hb level together with a significant increase in the platelet count 12w after the end of treatment compared to their baseline values. A finding that could be considered another advantage of DAAs therapy besides its efficacy, especially in this group of decompensated cirrhosis in whom cytopenia is a common finding.
Needless to say that, the non significant decrease in Hb level observed 12w after the end of treatment could be related to the use of ribavirin, however being non significant, none of our treated patients required transfusion and/or discontinuation of ribavirin. Consequently, most of these cases were managed by decreasing the ribavirin dose and in some cases addition of epoetin.
Likewise, since platelet count is an indirect marker of portal hypertension, the significant increase in the platelet count observed 12w after the end of treatment in our study group indicates improvement in portal hypertension in these patients.
Interestingly, before treatment, the majority (80%) of our treated patients were ascitic (24/30) and ascites was marked in 3 patients (10%), mod-% erate in 8 patients (26.7%) and mild in 13 patients (43.3%). After DAAs therapy, ascites was detected only in 15 patients (50%) which was moderate in 4 patients (13.3%) and mild in 11 patients (36.7%) indicating marked improvement both in the incidence as well as in the volume of ascitic fluid 12w after the end of treatment.
It is noteworthy to mention that, on extended follow-up, 10 of our ascitic patients stopped diuretic therapy and the remaining 14 patients still on a reduced dose of diuretic therapy. Needless to say that, this marked improvement in both the frequency as well as the volume of ascites indicates not only improvement in liver functions, but also will be associated with marked improvement in the quality of life of these patients.
Review of relevant publications revealed some discrepancies between our results and the results of other studies. The single national study conducted by Salama et al., [12] also reported a significant improvement in ascites in their Egyptian HCV genotype 4 ascitic patients treated with DAAs therapy. While, the study of Deterding et al., reported a non significant improvement in ascites in their treated patients. However, McCaughan et al., [11] reported significant improvement in most of the cases and worsening of ascites in some of their treated ascitic HCV patients.
The clinically most important finding of this study is that CTP score significantly improved from 8.33 ± 1.63 before treatment to 7.27 ±01.62 12 weeks after the end of therapy ( p=0.05). A finding that has major implications in the management of HCV infection with advanced cirrhosis. This finding supports the concept that intrahepatic inflammation directly contributes to reduced synthetic capacity of the liver and that blocking inflammation can restore liver function to some extent. In view of this finding, by DAAs therapy, further progression of liver disease can potentially be halted and the number of patients requiring liver transplantation possibly can be reduced.
Similar results were also reported by the other national study [12] and 2 other international studies [6, 7] in whom improvement of both CTP and MELD score was observed in the majority of their treated patients.
It is noteworthy to mention that, concerning efficacy and antiviral response, the 12/24 weeks therapy with the 4 different combinations of DAAs therapy achieved SVR in all treated patients (100%). Moreover, no virologic failure was observed in any of our treated patients. Review of relevant publications revealed some discrepancies between our results and the other international studies. Almost all other international studies reported a lower SVR rate in their patients with advanced cirrhosis treated with DAAs therapy [6, 7, 10, 11] .
The higher SVR rate reported in our study compared to these international studies may be related to differences in sample size as well as HCV genotypes treated in these studies.
Regarding safety outcomes, all treatment-related adverse events were reported during the study period. The most common were minor adverse events in the form of anaemia in 17 (56.7%) patients, headache in 15 (37.5%) patients, fatigue in 14 (35%), nausea in 13 (32.5%), itching in 10 (25%), fever in 9 (22.5%) and DM in one patient (2.5%). Most of these adverse events were managed conservatively and non of our cohort discontinued treatment prematurely or required dose adjustment of the treatment regimen.
On the other hand, 3 patients (7.5%) died on treatment after achieving RVR, 2 from liver cell failure and one from sepsis (chest infection). Almost similar results were reported by the other national and 2 international studies. Salama et al., [12] reported 9.3%, while McCaughan et al., [13] and Charlton et al., [7] reported 10.2% and 9.3% respectively.
Very importantly, on further subanalysis, the mean initial CTP score of the 3 patients who died during treatment in our study was 12.7 compared to 8.33 ± 1.63 in those patients who successfully completed treatment. Such baseline high CTP score may be considered a factor that predict mortality in patients with advanced decompensated disease who receive DAAs therapy and possibly suggesting a point of no return in these patients. It is important to note that, we need future large studies to define specific characteristics of such patients who may not benefit from these novel DAAs therapy and for whom post-transplant treatment of HCV may be a reasonable approach.
Additionally, on futher extended follow-up beyond the study period, 2 of our patients (5%) developed HCC 6 months after achieving SVR. A finding that clearly shows that in patients with chronic hepatitis C and decompensated cirrhosis, HCC may still develops despite achieving a SVR. Therefore, careful monitoring and surveillance for HCC should be done even after achieving a SVR in patients with advanced cirrhosis.
Safety & Efficacy of Directly Acting Antiviral Therapy in Hepatitic C
Finally, based on the results of this real-world study, it is now possible to treat patients with HCV and advanced decompensated cirrhosis who were largely untreated previously, the combination of different DAAs regimens with or without ribavirin for 12 or 24w respectively is not only highly effective with SVR12 rate of 100%, but also safe and well tolerated in this group of Egyptian HCV G4 patients with decompensated cirrhosis. Moreover, the significant improvement in liver function parameters observed in this study can potentially halt progression of liver disease and consequently the number of patients requiring liver transplantation possibly can be reduced. Thus, providing a new hope for these critically ill patients. However, the timing as well as the overall approaches to treat patients with advanced decompensated liver disease remains challenging.
